March 25, 2021 10:14 AM EDT
Pharma
FDA+
Coronavirus

US to no longer dis­trib­ute Eli Lil­ly’s bam­lanivimab alone due to coro­n­avirus vari­ants

Zachary Brennan

Senior Editor

The US gov­ern­ment and Eli Lil­ly agreed to halt all dis­tri­b­u­tion of the com­pa­ny’s Covid-19 mon­o­clon­al an­ti­body bam­lanivimab as of Wednes­day due to the sus­tained …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times